[Plasma and urinary CEA-assay in patients with urological tumours (author's transl)].
Plasma and urinary carcino-embryonic antigen (CEA) assays were performed in 151 patients with urological tumours. CEA measurement is unreliable in renal cell carcinoma and carcinoma of the prostate. However, CEA-assays permit the diagnosis of bladder tumours. The test is particularly useful in the followup and therapeutic control of patients with carcinoma of the bladder.
D000230:Adenocarcinoma / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000032:analysis* / Q000652:urine; D002291:Carcinoma, Papillary / Q000652:urine; D002294:Carcinoma, Squamous Cell / Q000652:urine; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology; D008297:Male; D009364:Neoplasm Recurrence, Local; D011471:Prostatic Neoplasms / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology; D014565:Urogenital Neoplasms / Q000276:immunology* / Q000652:urine
D002272:Carcinoembryonic Antigen
CEA-Bestimmung in Urin und Plasma bei Patienten mit Tumoren des Urogenitaltraktes